Eli Lilly and Company

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).

1,341 total trials 124 currently recruiting 1029 completed early-phase tilt top decile by trial count

Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.

Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.

Top-decile sponsor footprint

Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 67/100

1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,341 total, page 9 of 27

COMPLETED Phase 1

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

NCT04081337
COMPLETED Phase 1

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

NCT04451408
COMPLETED Phase 2

A Study of LY3209590 in Participants With Type 1 Diabetes

NCT04450407
COMPLETED Phase 2

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

NCT04450394
COMPLETED Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis

NCT04456686
TERMINATED Phase 3

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396574
COMPLETED Phase 1

A Study of LY3832479 (LY-CoV016) in Healthy Participants

NCT04441931
COMPLETED Phase 2

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

NCT04427501
COMPLETED Phase 1

A Study of LY3461767 in Healthy Participants

NCT04352114
COMPLETED Phase 3

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

NCT04392154
TERMINATED Phase 3

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396236
COMPLETED Phase 3

A Study of Baricitinib (LY3009104) in Participants With COVID-19

NCT04421027
COMPLETED Phase 3

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT04255433
COMPLETED Phase 1

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

NCT04411628
COMPLETED Phase 2

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

NCT04004611
TERMINATED Phase 2

A Study of LY3127804 in Participants With COVID-19

NCT04342897
COMPLETED Phase 1

A Study of LY3478045 in Healthy Participants

NCT04270370
TERMINATED Phase 1

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

NCT04145700
COMPLETED Phase 1

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

NCT04172987
TERMINATED Phase 1

A Study of LY3478006 in Healthy Participants

NCT04230122
COMPLETED Phase 4

A Study of Baricitinib in Participants With Rheumatoid Arthritis

NCT04086745
COMPLETED Phase 3

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350
COMPLETED Phase 1

A Study of Two Formulations of Ixekizumab in Healthy Participants

NCT04259346
COMPLETED Phase 3

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

NCT04250337
COMPLETED Phase 1

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937
COMPLETED Phase 1

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT04143802
COMPLETED Phase 3

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

NCT04184622
TERMINATED Phase 1

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

NCT04165031
COMPLETED Phase 1

A Study of LY3556050 in Healthy Participants

NCT04156750
TERMINATED Phase 1

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

NCT04152382
COMPLETED Phase 2

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773
TERMINATED Phase 2

A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

NCT04159701
COMPLETED Phase 3

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

NCT04178967
TERMINATED Phase 1

A Study of LY3435151 in Participants With Solid Tumors

NCT04099277
COMPLETED Phase 1

A Safety Study of LY3372689 in Healthy Participants

NCT04106206
COMPLETED Phase 3

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

NCT04146363
COMPLETED Phase 1

A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

NCT04050670
TERMINATED Phase 3

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

NCT03843125
COMPLETED Phase 1

A Study of LY3475766 in Healthy Participants

NCT04052594
COMPLETED Phase 3

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

NCT04039503
TERMINATED Phase 4

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885
TERMINATED Phase 1

A Study of LY3154885 in Healthy Participants

NCT04014361
COMPLETED Phase 1

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

NCT03955939
COMPLETED Phase 1

A Study of LY3214996 in Healthy Participants

NCT04033341
COMPLETED Phase 3

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919
COMPLETED Phase 3

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT03926130
COMPLETED Phase 1

A Study of Tirzepatide in Participants With Impaired Liver Function

NCT03940742
COMPLETED Phase 1

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

NCT03988088
COMPLETED Phase 1

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

NCT03898791
COMPLETED Phase 3

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

NCT03899259
← Previous Page 9 of 27 Next →

Phase Distribution

PhaseTrial count
Phase 1 517
Phase 2 344
Phase 3 368
Phase 4 91

Therapeutic Areas

Healthy 55
Obesity 48
Overweight 37
Type 2 Diabetes 20
Neoplasm Metastasis 15
Diabetes Mellitus, Type 2 14
Alzheimer Disease 13
Carcinoma, Non-Small Cell Lung 11
Breast Cancer 11
Non-Small Cell Lung Cancer 11

What is open in the Eli Lilly and Company pipeline

124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).

Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).

Top condition: Healthy (55 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Eli Lilly and Company: open-pipeline peers nationwide

Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Eli Lilly and CompanyGlaxoSmithKlineUniversity of MichiganNovartis PharmaceuticalsAstraZenecaShionogiUniversity of KentuckyUniversity of VermontLahey Clinic
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,341 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Eli Lilly and Company page

1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.

  • 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.